logo-loader

Motif Bio celebrates 'major milestone' in antibiotic trial'

Published: 14:09 31 Jan 2017 GMT

Motif Bio Plc (LON:MTFB) has passed a major landmark after treating the final patient taking part in the first of two phase III clinical trials of its next-generation antibiotic, iclaprim.

Chief executive Graham Lumsden tells Proactive: ''This was a major milestone for us to be able to announce that we've finally completed the treatment phase for all 600 patients in this REVIVE-1 trial''.

Successful completion of the two final-stage trials should pave the way for regulatory submissions ahead of the formal green light of the drug in the US and Europe for patients with acute bacterial skin and skin structure infections (ABSSSI).

Accesso's landmark deal with SEVEN marks strategic growth in the Saudi Market

Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF) chief executive Steve Brown joins Proactive's Stephen Gunnion with details of a significant partnership with Saudi Entertainment Ventures (SEVEN). Brown noted the collaboration highlights accesso's strategy to grow its global footprint,...

3 minutes ago